GT Biopharma (GTBP) Competitors $1.74 -0.18 (-9.11%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GTBP vs. INKT, LSTA, CLDI, ATHA, MTEX, GOVX, IBIO, PULM, NNVC, and INABShould you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include MiNK Therapeutics (INKT), Lisata Therapeutics (LSTA), Calidi Biotherapeutics (CLDI), Athira Pharma (ATHA), Mannatech (MTEX), GeoVax Labs (GOVX), iBio (IBIO), Pulmatrix (PULM), NanoViricides (NNVC), and IN8bio (INAB). These companies are all part of the "pharmaceutical products" industry. GT Biopharma vs. MiNK Therapeutics Lisata Therapeutics Calidi Biotherapeutics Athira Pharma Mannatech GeoVax Labs iBio Pulmatrix NanoViricides IN8bio GT Biopharma (NASDAQ:GTBP) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, community ranking, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment. Is GTBP or INKT more profitable? MiNK Therapeutics' return on equity of 0.00% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets GT BiopharmaN/A -257.47% -131.09% MiNK Therapeutics N/A N/A -189.14% Does the media prefer GTBP or INKT? In the previous week, GT Biopharma and GT Biopharma both had 1 articles in the media. GT Biopharma's average media sentiment score of 0.92 beat MiNK Therapeutics' score of 0.00 indicating that GT Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GT Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiNK Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer GTBP or INKT? GT Biopharma presently has a consensus target price of $11.00, suggesting a potential upside of 530.37%. MiNK Therapeutics has a consensus target price of $6.50, suggesting a potential upside of 1,140.46%. Given MiNK Therapeutics' higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than GT Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in GTBP or INKT? GT Biopharma received 102 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. However, 75.00% of users gave MiNK Therapeutics an outperform vote while only 63.24% of users gave GT Biopharma an outperform vote. CompanyUnderperformOutperformGT BiopharmaOutperform Votes11763.24% Underperform Votes6836.76% MiNK TherapeuticsOutperform Votes1575.00% Underperform Votes525.00% Which has preferable earnings & valuation, GTBP or INKT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGT BiopharmaN/AN/A-$7.60MN/AN/AMiNK TherapeuticsN/AN/A-$22.46M-$0.39-1.34 Do institutionals and insiders hold more shares of GTBP or INKT? 8.1% of GT Biopharma shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 10.9% of GT Biopharma shares are held by insiders. Comparatively, 19.7% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, GTBP or INKT? GT Biopharma has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500. SummaryGT Biopharma beats MiNK Therapeutics on 8 of the 13 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTBP vs. The Competition Export to ExcelMetricGT BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.29M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.1317.19Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.325.094.784.78Net Income-$7.60M$151.83M$120.31M$225.60M7 Day Performance-36.55%-2.14%-1.92%-1.23%1 Month Performance-42.97%-4.56%13.65%0.46%1 Year Performance-77.65%8.87%28.34%15.24% GT Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTBPGT Biopharma3.6544 of 5 stars$1.75-9.1%$11.00+530.4%-78.3%$4.29MN/A0.008Positive NewsGap UpINKTMiNK Therapeutics2.2338 of 5 stars$0.59-5.0%$6.50+1,011.1%-48.4%$23.14MN/A-1.4930Gap UpLSTALisata Therapeutics1.8982 of 5 stars$2.70+4.7%$15.00+455.6%-4.9%$22.67MN/A-1.1030CLDICalidi Biotherapeutics2.3407 of 5 stars$1.73-6.5%$16.67+863.7%N/A$22.62M$50,000.000.0041News CoverageGap DownATHAAthira Pharma2.1034 of 5 stars$0.58-0.5%$13.83+2,276.5%-71.9%$22.51MN/A-0.2140MTEXMannatech0.2142 of 5 stars$11.85+13.6%N/A+56.8%$22.28M$131.96M-13.90250Analyst ForecastGap UpGOVXGeoVax Labs2.9322 of 5 stars$2.32-1.3%$14.20+512.1%-55.9%$21.89M$3.09M0.0017Analyst ForecastNews CoverageIBIOiBio0.988 of 5 stars$2.35+1.7%$4.30+83.0%N/A$21.50M$175,000.000.00100PULMPulmatrix0.1939 of 5 stars$5.85+1.7%N/A+198.5%$21.35M$7.30M-2.1820Analyst ForecastNews CoverageNNVCNanoViricidesN/A$1.49+0.7%N/A+40.6%$20.78MN/A-1.9520INABIN8bio3.644 of 5 stars$0.28-0.3%$7.75+2,628.9%-80.7%$20.59MN/A-0.3820Gap Down Related Companies and Tools Related Companies MiNK Therapeutics Alternatives Lisata Therapeutics Alternatives Calidi Biotherapeutics Alternatives Athira Pharma Alternatives Mannatech Alternatives GeoVax Labs Alternatives iBio Alternatives Pulmatrix Alternatives NanoViricides Alternatives IN8bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GTBP) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
